lifestyle.phenomena.org

Author: Skyhawk Therapeutics

/C O R R E C T I O N — Skyhawk Therapeutics/

May 18, 2026
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule

May 18, 2026
Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society’s 2026 Medal of Honor

March 30, 2026
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington’s Disease

March 10, 2026
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

January 27, 2026